Health · 1 sources covering this

STAT+: Longevity startup Retro Biosciences says latest fundraising values it at $1.8 billion

Retro Biosciences, the longevity startup backed by OpenAI CEO Sam Altman, has raised more money at a $1.8 billion valuation, it announced Friday.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·7h ago
STAT+: Longevity startup Retro Biosciences says latest fundraising values it at $1.8 billion
Retro Biosciences, the longevity startup backed by OpenAI CEO Sam Altman, has raised more money at a $1.8 billion valuation, it announced Friday.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/9796f72ebb4fec7545dbdf24276fe02006238b54"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Longevity startup Retro Biosciences says latest fundraising values it at $1.8 billion"></iframe>

STAT+: Longevity startup Retro Biosciences says latest fundraising values it at $1.8 billion

How 1 sources are covering this

STAT+: Longevity startup Retro Biosciences says latest fundraising values it at $1.8 billion

More from Health

STAT+: Congress slashed Medicaid funding to providers. The Trump administration wants to cut even further

STAT+: EU and US advisers split over AstraZeneca breast cancer drug

STAT+: Pharmalittle: We’re reading about a Parkinson’s drug setback, a Merck lung cancer therapy, and more

A CDC page on mpox caught in political crosshairs

Reader

Trust & legal

Across the network

How 1 sources are covering this

STAT+: Longevity startup Retro Biosciences says latest fundraising values it at $1.8 billion

More from Health

STAT+: Congress slashed Medicaid funding to providers. The Trump administration wants to cut even further

STAT+: EU and US advisers split over AstraZeneca breast cancer drug

STAT+: Pharmalittle: We&#8217;re reading about a Parkinson&#8217;s drug setback, a Merck lung cancer therapy, and more

A CDC page on mpox caught in political crosshairs

Reader

Trust & legal

Across the network

STAT+: Pharmalittle: We’re reading about a Parkinson’s drug setback, a Merck lung cancer therapy, and more